Supreme Court Weighs Telemedicine Access for Abortion Pill Amid Legal Challenges
The U.S. Supreme Court is currently deliberating on a significant case concerning telemedicine access to the abortion pill mifepristone. This follows a decision by the 5th Circuit Court of Appeals, which reinstated the requirement for in-person consultations for medication abortions, effectively rolling back telemedicine access nationwide. The Supreme Court has temporarily stayed this decision, allowing telemedicine prescriptions to continue until May 11. The case originated from Louisiana, which argued that telemedicine undermines its strict abortion laws. The Department of Justice, representing the FDA, has not filed a defense for the agency's 2023 rule allowing telemedicine prescriptions, raising questions about the FDA's regulatory authority. 
